Actual 10-year Outcomes of Tacrolimus/MMF Compared with Cyclosporin/MMF in Kidney Transplantation.
10.4285/jkstn.2014.28.2.69
- Author:
Yaerim KIM
1
;
Sungbae PARK
;
Hyoungtae KIM
;
Seungyeup HAN
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. hansy@dsmc.or.kr
- Publication Type:Original Article
- Keywords:
Kidney transplantation;
Cyclosporin;
Tacrolimus
- MeSH:
Allografts;
Cyclosporine;
Follow-Up Studies;
Graft Survival;
Humans;
Hyperlipidemias;
Hypertension;
Immunosuppressive Agents;
Incidence;
Kidney;
Kidney Transplantation*;
Renal Insufficiency, Chronic;
Research Report;
Survival Rate;
Tacrolimus
- From:The Journal of the Korean Society for Transplantation
2014;28(2):69-77
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Kidney transplantation is the most effective treatment in patients with chronic kidney disease. Recently, the survival rate of kidney allografts has been markedly increased by the development of immunosuppressants. According to research reports published in Symphony in 2007 and 2009, low dose tacrolimus/mycophenolate mofetil (MMF) showed better results than cyclosporin/MMF in renal function and rejection. METHODS: We compared patient survival rate, graft survival rate, incidence of rejection, and metabolic complications in two groups of patients who received immunosuppressants with either tacrolimus/MMF/steroid or cyclosporin/MMF/steroid. All patients underwent kidney transplants at Keimyung University Dongsan Medical Center between January 1997 and December 2003 with follow-up over 10 years. RESULTS: A total of 180 patients were included in the research (117 patients were treated with tacrolimus/MMF/steroid and 63 patients with cyclosporin/MMF/steroid). The incidence rate of acute rejection was higher in the cyclosporin/MMF/steroid group; however, the difference was not statistically significant. In the case of metabolic complications, new onset diabetes after transplantation was more frequent in the tacrolimus/MMF/steroid group. The cyclosporin/MMF/steroid group appeared to have a higher rate of hypertension and hyperlipidemia. CONCLUSIONS: Overall, no significant differences in patient and graft survival rate were observed between the two groups.
